Literature DB >> 19820224

Progress in measurement instruments for acute and chronic gout studies.

Rebecca Grainger1, William J Taylor, Nicola Dalbeth, Fernando Perez-Ruiz, Jasvinder A Singh, Royce W Waltrip, Naomi Schlesinger, Robert Evans, N Lawrence Edwards, Francisca Sivera, Cesar Diaz-Torne, Patricia A MacDonald, Fiona M McQueen, H Ralph Schumacher.   

Abstract

Consensus exercises have identified and prioritized domains of measurement for studies in acute and chronic gout. In parallel, the technical properties of instruments for measurement in many of these domains have been assessed, with the main objective to consider the instruments in the context of the OMERACT filter of truth, discrimination, and feasibility. These data were presented and discussed at OMERACT 9 in the gout workshop, in breakout groups, and at informal meetings of the gout group. In acute gout, instruments for domains of pain, joint swelling, joint tenderness, and patient and physician global assessment have been assessed. In chronic gout, some validation exercises have been performed in instruments for domains serum urate, tophus measurement, health-related quality of life (HRQOL). In voting at OMERACT 9, the Medical Outcomes Study Short-Form 36 was endorsed as a valid instrument for measurement of HRQOL. Methods of tophus measurement were considered to have met some criteria of the OMERACT filter, but these require further work, particularly regarding sensitivity to change over shorter time periods. Priorities for future research include measurement of joint inflammation in acute gout and disability in acute and chronic gout.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19820224     DOI: 10.3899/jrheum.090371

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

1.  Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities.

Authors:  Nicola Dalbeth; Fiona M McQueen; Jasvinder A Singh; Patricia A MacDonald; N Lawrence Edwards; H Ralph Schumacher; Lee S Simon; Lisa K Stamp; Tuhina Neogi; Angelo L Gaffo; Puja P Khanna; Michael A Becker; William J Taylor
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

Review 2.  Outcome measures in acute gout: a systematic literature review.

Authors:  Nicola Dalbeth; Cathy S Zhong; Rebecca Grainger; Dinesh Khanna; Puja P Khanna; Jasvinder A Singh; Fiona M McQueen; William J Taylor
Journal:  J Rheumatol       Date:  2013-12-15       Impact factor: 4.666

3.  OMERACT endorsement of measures of outcome for studies of acute gout.

Authors:  Jasvinder A Singh; William J Taylor; Nicola Dalbeth; Lee S Simon; John Sundy; Rebecca Grainger; Rieke Alten; Lyn March; Vibeke Strand; George Wells; Dinesh Khanna; Fiona McQueen; Naomi Schlesinger; Annelies Boonen; Maarten Boers; Kenneth G Saag; H Ralph Schumacher; N Lawrence Edwards
Journal:  J Rheumatol       Date:  2013-12-15       Impact factor: 4.666

4.  2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis.

Authors:  Dinesh Khanna; Puja P Khanna; John D Fitzgerald; Manjit K Singh; Sangmee Bae; Tuhina Neogi; Michael H Pillinger; Joan Merill; Susan Lee; Shraddha Prakash; Marian Kaldas; Maneesh Gogia; Fernando Perez-Ruiz; Will Taylor; Frédéric Lioté; Hyon Choi; Jasvinder A Singh; Nicola Dalbeth; Sanford Kaplan; Vandana Niyyar; Danielle Jones; Steven A Yarows; Blake Roessler; Gail Kerr; Charles King; Gerald Levy; Daniel E Furst; N Lawrence Edwards; Brian Mandell; H Ralph Schumacher; Mark Robbins; Neil Wenger; Robert Terkeltaub
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-10       Impact factor: 4.794

5.  Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials.

Authors:  Jasvinder A Singh; Shuo Yang; Vibeke Strand; Lee Simon; Anna Forsythe; Steve Hamburger; Lang Chen
Journal:  Ann Rheum Dis       Date:  2011-07       Impact factor: 19.103

6.  Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout.

Authors:  Puja P Khanna; Fernando Perez-Ruiz; Paul Maranian; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2010-12-08       Impact factor: 7.580

Review 7.  Non-steroidal anti-inflammatory drugs for acute gout.

Authors:  Caroline Mpg van Durme; Mihir D Wechalekar; Robert Bm Landewé; Jordi Pardo Pardo; Sheila Cyril; Désirée van der Heijde; Rachelle Buchbinder
Journal:  Cochrane Database Syst Rev       Date:  2021-12-09

8.  Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout.

Authors:  Nicola Dalbeth; Meaghan E House; Anne Horne; William J Taylor
Journal:  BMC Musculoskelet Disord       Date:  2013-12-21       Impact factor: 2.362

9.  Development and First Validation of a Disease Activity Score for Gout.

Authors:  Carlo A Scirè; Greta Carrara; Cinzia Viroli; Marco A Cimmino; William J Taylor; Maria Manara; Marcello Govoni; Fausto Salaffi; Leonardo Punzi; Carlomaurizio Montecucco; Marco Matucci-Cerinic; Giovanni Minisola
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-09-06       Impact factor: 4.794

10.  What Outcomes are Important for Gout Patients? In-Depth Qualitative Research into the Gout Patient Experience to Determine Optimal Endpoints for Evaluating Therapeutic Interventions.

Authors:  Sophi Tatlock; Katja Rüdell; Charlotte Panter; Rob Arbuckle; Leslie R Harrold; William J Taylor; Tara Symonds
Journal:  Patient       Date:  2017-02       Impact factor: 3.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.